Lisata Therapeutics Inc (NAS:LSTA)
$ 2.77 -0.045 (-1.6%) Market Cap: 23.01 Mil Enterprise Value: -20.16 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 41/100

Lisata Therapeutics Inc Fireside Chat Hosted by H.C. Wainwright & Co LLC (Virtual) Transcript

Jun 21, 2023 / 03:00PM GMT
Release Date Price: $3.91 (-1.26%)
Joseph Pantginis
H.C. Wainwright & Co, LLC, Research Division - Director of Research & MD of Equity Research

Okay. Good morning, everybody. My name is Joseph Pantginis, here at H.C. Wainwright. I'm the Director of Research and Managing Director of Equity Research as well. Very happy to provide this fireside chat with Lisata Therapeutics today. I've been covering the company for quite a long time even before when it was Caladrius. So it's been a very interesting ride and very happy to keep covering it. We do have a buy rating from a disclosure standpoint on Lisata.

And we're very happy to have with us David Mazzo, who is President and CEO; as well as Kristen Buck, who's the Executive Vice President of R&D and the Chief Medical Officer of the company. So thank you very much for being with us today, and I'd say let's just dive right in.

Questions & Answers

Joseph Pantginis
H.C. Wainwright & Co, LLC, Research Division - Director of Research & MD of Equity Research

So David and Kristen, like I said, thanks for joining us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot